Lipid nanoparticles enable targeted RNA therapy for inflammatory bowel diseases
Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable type of RNA—to treat inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The researchers encapsulated selected LNA molecules,